title: Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome.
abstract: BACKGROUND
  Hyperuricaemia commonly occurs in renal transplant recipients (RTRs), but the effects of post-transplant hyperuricaemia on kidney transplant outcome have not been clearly established. This work was designed to explore the impact of hyperuricaemia on renal transplant outcome.
  
  
  METHODS
  The authors examined this issue by analysing the clinical outcome of 281 RTRs. Hyperuricaemia (defined as UA > 7.0 mg/dl in men and >6.0 mg/dl in women for at least two consecutive tests, n = 121) was classified as early onset (within 1 year of transplant, n = 90) or late onset (n = 31). Graft function was estimated using the MDRD Study Equation 7 (eGFR(MDRD)).
  
  
  RESULTS
  As late-onset hyperuricaemia was found to be induced by a progressive decline in the graft function (P < 0.01), data from early-onset hyperuricaemic recipients were used. Early-onset moderate-to-severe hyperuricaemia (defined as UA >or= 8.0 mg/dl) was found to be a significant risk factor for chronic allograft nephropathy (P = 0.035) and a poorer graft survival (P = 0.026) by multivariate analysis, whereas mild hyperuricaemia was not. The impact of moderate-to-severe hyperuricaemia on renal transplant survival was dependent on the duration of exposure. Likewise, the detrimental effect of early-onset hyperuricaemia on the graft function was dependent on UA levels and exposure time. After control of the baseline graft function by analysis of only recipients with a good graft function at 1 year post-transplantation (eGFR(MDRD) > 60 ml/min), moderate-to-severe early-onset hyperuricaemia was also found to be a marker of long-term graft dysfunction and failure.
  
  
  CONCLUSIONS
  Moderate-to-severe early-onset hyperuri- caemia may be a prognostic marker of the long-term graft outcome in RTRs, which needs further investigation.
authors.affiliation: Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Sang Il
authors.initials: SI
authors.lastname: Min
authors.forename: Ik Jin
authors.initials: IJ
authors.lastname: Yun
authors.forename: Jin Mo
authors.initials: JM
authors.lastname: Kang
authors.forename: Yang Jin
authors.initials: YJ
authors.lastname: Park
authors.forename: Seung Kee
authors.initials: SK
authors.lastname: Min
authors.forename: Curie
authors.initials: C
authors.lastname: Ahn
authors.forename: Sang Joon
authors.initials: SJ
authors.lastname: Kim
authors.forename: Jongwon
authors.initials: J
authors.lastname: Ha
mesh_terms: D000328:Adult; D017668:Age of Onset; D015415:Biomarkers / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D033461:Hyperuricemia / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D011379:Prognosis; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
chemical_list: D015415:Biomarkers; D014527:Uric Acid